30 Nov 2012, BioSpectrum Bureau , BioSpectrum
Singapore: US-based PharmaJet entered into a collaboration with CSL to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as early as the 2013-14 flu season. Adding PharmaJet jet injectors to the Afluria label will expand the delivery options for flu vaccine administration, thereby helping to broaden immunization coverage.
PharmaJet injectors use pressure to create a fine stream of liquid that penetrates the skin, delivering doses to the desired depth, while eliminating needle-stick injuries, needle anxiety and the cost burden of 'sharps' disposal management. The PharmaJet Stratis device has received FDA 510(k) marketing clearance and provides easy and affordable injections, delivering vaccine in one-fifth of a second and with reduced pain sensation.
Afluria, a CSL product, is a non-adjuvanted seasonal influenza vaccine sold in two different formulations, including thimerosal-free, pre-filled syringes, and in multi-dose vials. CSL Biotherapies and PharmaJet are working to include jet injectors as a method of administration on the Afluria label in time for the 2013-14 flu season.
PharmaJet's collaboration with CSL involves conducting a phase IV clinical study to demonstrate the immunogenicity and safety of Afluria, presented in multi-dose vials, when administered with PharmaJet Stratis needle-free device. Pending favorable clinical results, CSL will submit a supplement to Afluria's BLA to include the option of needle-free jet injection on the Afluria labeling.